Gilead Sciences Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five decreased by 50.5% to $982.00M in Q1 2026 compared to the prior quarter.
Changes in this bucket reflect shifts in the company's duration management and medium-term reinvestment strategy.
This represents the amortized cost of debt securities in the available-for-sale portfolio that have maturity dates betwe...
Standard maturity bucket reporting for insurance investment portfolios.
other_available_for_sale_securities_debt_maturities_afte_2b276a| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $814.00M | $1.08B | $1.41B | $1.34B | $1.30B | $1.33B | $1.33B | $1.16B | $1.90B | $1.98B | $982.00M |
| QoQ Change | — | +32.1% | +31.5% | -5.4% | -3.0% | +2.1% | +0.5% | -12.8% | +63.7% | +4.4% | -50.5% |
| YoY Change | — | — | — | +64.4% | +20.7% | -6.3% | -0.4% | -10.6% | — | — | — |